表皮生长因子受体表达与乳腺癌激素受体水平和预后的关系

应用免疫组化ＡＢＣ方法研究７５例乳腺癌冰冻组织表皮生长因子受体（ＥＧＦＲ）的表达，结合临床资料和ＥＲ、ＰＲ测定结果进行分析，探讨ＥＧＦＲ表达与乳腺癌预后的关系。结果表明，ＥＧＦＲ阳性３０例（４０％），ＥＧＦＲ表达与肿瘤大小、腋淋巴结状况，临床分期和年龄无关，与ＥＲ、ＰＲ存在着显著的负相关（Ｐ＜０．００５）。全组中位随诊时间为６０个月，ＥＧＦＲ阳性组术后总生存率明显低于阴性组（Ｐ＜０．００１）。在无腋淋巴结转移的病例中，ＥＧＦＲ阳性组和阴性组术后生存情况也有显著差异（Ｐ＜０．０１），提示ＥＧＦＲ表达与乳腺癌不良的预后有关。调整分析乳腺癌有关的预后因素，各组病例中均以ＥＧＦＲ表达阳性组的预后为差，说明ＥＧＦＲ对乳腺癌预后具有独立的作用，不受其他因素的影响。经Ｃｏｘ模型多因素分析显示，ＥＧＦＲ和腋淋巴结受累与否是对乳腺癌术后生存情况有显著性影响的两个因素。

Expression of Epidermal Growth Factor Receptor in Breast Cancer-Its Prognostic Significance and Relation with Steroid Hormone Receptors

Immunocytochemical assay for epidermal growth factor receptor(EGFR)was made on frozen sections of 75 breast cancer specimens in an attempt to correlate the results with the Prognosis.Overall,40% of the tumors were EGFR positive.The positivity of EGFR was not related to tumor size, lymph node status, stage of the disease or age of the patients,rather was negatively correlated with positivity status of oestrogen(ER)and progesterone(PR)receptors(P<0.005).The median follow -up of patients was 60 months The overall survival was significantly worse for patients with EGFR-positive tumors compared with EGPR-negative tumors(P<0.001)In nodenegative patients there was a significantly higher death rate for patients with EGFR positive tumors. EGFR has been shown to be a marker of poor prognosis for breast cancer patients When patients were grouped in terms of tumor size stage lymph node status ER and PR status the prognosis tended to become worse for patients with EGFR positive tumors Multivariate analysis showed that EGFR-positive and lymph node in volovement were two key prognostic factors in breast cancer patients.